Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lentz

Showing results (51-60 of 106) with videos related to

Pageof 11
Sort By:
Gynecologic Oncology|September 19, 2003
Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group studyJ Tate Thigpen, John A Blessing, George Olt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group studyW P McGuire, J A Blessing, D Moore, et al.
Annals of Plastic Surgery|February 1, 1997
Reconstruction of pelvic exenterative wounds with transpelvic rectus abdominis flaps: a case seriesA K Jain, A J DeFranzo, M W Marks, et al.
Bioorganic & Medicinal Chemistry Letters|September 10, 2013
New chemotypes for wALADin1-like inhibitors of delta-aminolevulinic acid dehydratase from Wolbachia endobacteriaChristian S Lentz, Dagmar Stumpfe, Juergen Bajorath, et al.
Gynecologic Oncology|June 12, 2003
Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group studyAllan Covens, Virginia L Brunetto, Maurie Markman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group StudyW P McGuire, J A Blessing, M A Bookman, et al.
Gynecologic Oncology|March 27, 2001
Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group studyM Markman, D Spriggs, R A Burger, et al.
American Journal of Obstetrics and Gynecology|September 1, 1987
Evaluation of the atypical Pap smearD E Jones, W T Creasman, R A Dombroski, et al.
Gynecologic Oncology|August 1, 1990
Effector function of lymphokine-activated killer cells and cytotoxic T lymphocytes in ovarian epithelial carcinomaS S Lentz, J S Kovach, D J McKean, et al.
Gynecologic Oncology|January 31, 2004
Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group studyJames V Fiorica, Virginia L Brunetto, Parviz Hanjani, et al.
Pageof 11

Showing results (51-60 of 106) with videos related to

Sort By:
Pageof 11
Gynecologic Oncology|September 19, 2003
Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group studyJ Tate Thigpen, John A Blessing, George Olt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group studyW P McGuire, J A Blessing, D Moore, et al.
Annals of Plastic Surgery|February 1, 1997
Reconstruction of pelvic exenterative wounds with transpelvic rectus abdominis flaps: a case seriesA K Jain, A J DeFranzo, M W Marks, et al.
Bioorganic & Medicinal Chemistry Letters|September 10, 2013
New chemotypes for wALADin1-like inhibitors of delta-aminolevulinic acid dehydratase from Wolbachia endobacteriaChristian S Lentz, Dagmar Stumpfe, Juergen Bajorath, et al.
Gynecologic Oncology|June 12, 2003
Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group studyAllan Covens, Virginia L Brunetto, Maurie Markman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group StudyW P McGuire, J A Blessing, M A Bookman, et al.
Gynecologic Oncology|March 27, 2001
Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group studyM Markman, D Spriggs, R A Burger, et al.
American Journal of Obstetrics and Gynecology|September 1, 1987
Evaluation of the atypical Pap smearD E Jones, W T Creasman, R A Dombroski, et al.
Gynecologic Oncology|August 1, 1990
Effector function of lymphokine-activated killer cells and cytotoxic T lymphocytes in ovarian epithelial carcinomaS S Lentz, J S Kovach, D J McKean, et al.
Gynecologic Oncology|January 31, 2004
Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group studyJames V Fiorica, Virginia L Brunetto, Parviz Hanjani, et al.
Pageof 11